Objective The prognostic factors of chronic necrotizing pulmonary aspergillosis remain unclear. We assessed the prognostic factors of all-cause mortality in patients with chronic necrotizing pulmonary aspergillosis, focusing especially on underlying pulmonary disease, first-line treatment and host predisposition. Methods We retrospectively analyzed the medical records of 194 patients negative for HIV who had chronic necrotizing pulmonary aspergillosis treated at our institution in Saitama, Japan. Results The patients (median age, 68.5 years) were followed over a median follow-up time of 2.6 years. The underlying pulmonary diseases consisted of previous pulmonary tuberculosis in 59 (30.4%) patients, emphysema in 39 (20.1%) patients, interstitial lung disease in 32 (16.5%) patients, nontuberculous mycobacteriosis in 29 (14.9%) patients and other diseases in 35 (18%) patients. The first-line treatments included observation in 65 (33.5%) patients, itraconazole in 56 (28.9%) patients, micafungin in 46 (23.7%) patients, voriconazole in 22 (11.3%) patients and amphotericin B (including liposomal amphotericin B) in five (2.6%) patients. The overall cumulative mortality rate was 50.2% at five years and 67.4% at 10 years. Multivariate Cox proportional hazard modeling found an older age, the presence of systemic comorbidities, baseline corticosteroid use, a body mass index of <18.5 kg/m 2 and a C-reactive protein level of ! 5.0 mg/dL to be negative prognostic factors for all-cause mortality.
Introduction
Chronic pulmonary aspergillosis (CPA) has been reported to occur in various forms: simple aspergilloma (1), complex aspergilloma (1), semi-invasive pulmonary aspergillosis (2) , chronic necrotizing pulmonary aspergillosis (CNPA) (3), chronic cavitary pulmonary aspergillosis (CCPA) (4) and chronic fibrosing pulmonary aspergillosis (CFPA) (4) . The most recent official American Thoracic Society (ATS) statement published in 2011 categorized aspergillosis as the fol-port (13) . Only the Korean report described a median survival time, 62 months, for CNPA patients (12) .
In patients with CPA, the body mass index (BMI) is an independent predictor of the prognosis (14) . However, the prognostic factors of CNPA have not been clarified using a large number of patients. Mortality after CNPA may be affected by underlying pulmonary disease, treatments and host predisposition. In the present study, we assessed the prognostic factors of CNPA in patients with this disease, especially with regard to underlying pulmonary diseases, firstline treatments and host predisposition. Partial results of this study were reported in a previously published abstract (15) .
Materials and Methods

Patients
We reviewed the medical records of 1,019 patients with positive serum Aspergillus antibodies (290 patients) and/or positive Aspergillus species isolation from respiratory samples (803 patients) obtained between January 1997 and March 2011 at Saitama Cardiovascular and Respiratory Center, Saitama, Japan. This study included 208 patients newly diagnosed with chronic forms of pulmonary aspergillosis and 11 patients with aspergilloma. Three patients with simultaneous CNPA and lung cancer were excluded. Therefore, we studied 194 CNPA patients fulfilling these diagnostic criteria: 1) compatible symptoms continuing for >1 month; 2) new consolidations or masses with/without cavities or new consolidations with preexisting cavity expansion; and 3) positive isolation of Aspergillus species from respiratory samples or positive serum antibodies to Aspergillus (complement fixation test; Meridian Bioscience Inc.; BioRad Laboratories, Inc.). These criteria were modified from those of Kohno et al. (16) . In this study, even if galactomannan antigens or serum Aspergillus antigens were positive, if the positivity was not confirmed, a definitive diagnosis was not made.
Study design
We collected clinical data for this retrospective cohort study from patient medical records and obtained baseline clinical parameters within one month of the initial diagnosis. We defined time zero as the earlier detection date of an Aspergillus culture or serum Aspergillus antibodies. The underlying pulmonary diseases were classified as previous pulmonary tuberculosis (Pre-Tb), emphysema, interstitial lung disease (ILD), nontuberculous pulmonary mycobacteriosis (NTM) and others. In patients with two or more underlying pulmonary diseases, one dominant disease was chosen by consensus. "Others" included prior lung surgery (n=10), active pulmonary tuberculosis (n=5), emphysematous bullae (n=4), pneumothorax (n=4) and other (n=9) conditions. First-line treatment was defined as antifungal drug administration initiated within six months of diagnosis and continued for more than two weeks. The first-line treatment was considered "no treatment" if no treatment was initiated within six months of diagnosis. The patients were followed through December 2011 or until death if death occurred before December 2011. The survival status was determined from medical records, telephone interviews or both. The institutional review board of Saitama Cardiovascular and Respiratory Center approved this study (2011028) .
Statistical analysis
The baseline characteristics for each underlying pulmonary disease, first-line treatment and number of treatment drugs received through the observational period were compared using Fisher's exact test for nominal variables and the Kruskal-Wallis test for continuous variables. To investigate the potential risk factors of mortality, we chose the following variables for the univariate Cox regression analysis: age, sex, smoking history, systemic comorbidities, underlying pulmonary disease, baseline corticosteroid use, BMI (current WHO BMI cut-off value for underweight: <18.5 kg/m 2 ), serum Aspergillus antibody status, serum Aspergillus galactomannan antigen status (cut-off value: 1.0; Bio-Rad Laboratories), β-D-glucan (20 pg/mL cut-off value; Seikagaku Corporation), hemoglobin, serum albumin, C-reactive protein (CRP) and first-line treatment. A multivariate Cox regression analysis with backward variable selection was then performed.
Patient survival was estimated using a Kaplan-Meier analysis, and the log-rank test was used to compare allcause mortality rates for each patient group. In all analyses, a p value of <0.05 was considered to be statistically significant. Missing data were classified as "unknown" and entered into each statistical analysis model. The data analysis was performed with the SAS version 9.1.3 software program (SAS Institute Inc.). 
Results
Patient characteristics at baseline
Patient characteristics according to the underlying pulmonary disease
At least one underlying pulmonary disease was present in (Table 1) .
Therapy
The treatments administered are shown in Table 2 . The first-line treatment comprised no treatment in 65 (33.5%) patients, itraconazole in 56 (28.9%) patients, micafungin in 46 (23.7%) patients, voriconazole in 22 (11.3%) patients and amphotericin B (including liposomal amphotericin B) in five (2.6%) patients. In many of the 65 patients whose firstline treatment was no treatment, the pathological locus was underlying lung disease, and, in some cases, treatment could not be continued for more than two weeks due to side effects. Of these 65 patients, 24 (12.4%) were later treated for progression of CNPA and 41 (21.1%) ultimately received no treatment. Throughout the observational period, 81 (41.8%), 48 (24.7%) and 24 (12.4%) patients received one, two and three or more antifungal agents, respectively. The median ages of the patients receiving no treatment only and of patients receiving one, two and three or more antifungal agents were 73.0, 68.8, 68.3 and 63.3 years, respectively, with significant differences (p=0.013). Complementary surgical treatment was administered in seven patients. Bronchial artery embolization procedures were performed in six patients with massive hemoptysis.
Patient characteristics in relation to first-line treatment
Patients with itraconazole as the first-line treatment received corticosteroids less frequently than did patients re- ceiving other treatments (Table 2) . Patients with a first-line treatment of micafungin more frequently had a high β-Dglucan level, anemia, hypoalbuminemia and elevation of the CRP level (Table 2) .
Mortality
Over a median follow-up period of 2.6 years (range, 0.01-13.23 years), death from any cause occurred in 88 (45.4%) patients. The overall cumulative mortality rate was 50.2% at five years and 67.4% at 10 years (Fig. 1, Table 1 ). Patient deaths were due to pneumonia (27.3%), progression of CNPA (26.1%), ILD (11.4%), lung cancer (3.4%), NTM (3.4%), other pulmonary diseases (8.0%), non-pulmonary diseases (6.8%) and unknown causes (13.6%). With the exception of one patient who was treated for only few days and was therefore assigned to the no treatment group, the causes of death in the 41 patients receiving no treatment only were not related to CNPA.
Prognostic factors of all-cause mortality
The all-cause mortality of each underlying pulmonary disease is shown in Fig. 1 . A significant difference between survival curves was shown by log-rank testing in patients with underlying pulmonary disease of Pre-Tb versus ILD (p=0.016). The 5-year mortality rate of voriconazole was 100% in this study (Table 2) . However, the survival curves in relation to first-line treatment were not significantly different (Fig. 2) . A multivariate Cox proportional hazard model showed an older age, the presence of systemic comorbidities, baseline corticosteroid use, a BMI of <18.5 kg/m 2 and a CRP level of ! 5.0 mg/dL to be negative prognostic factors of all-cause mortality (Table 3) .
Discussion
We investigated patients with CNPA to assess prognostic factors for all-cause mortality, especially in relation to underlying pulmonary disease, first-line treatment and host predisposition. Among the five underlying pulmonary diseases observed, ILD resulted in a higher patient mortality rate than did Pre-Tb. However, underlying pulmonary disease and first-line treatment were not found to be prognostic factors for all-cause mortality in a Cox proportional hazard model.
In the present study, all patients had at least one underlying pulmonary disease, with NTM being the fourth leading underlying pulmonary disease. Kobashi and coworkers highlighted the importance of making an early diagnosis of CNPA during NTM follow-up (17) .
Binder and coworkers proposed the new clinical disease entity of CNPA in 1982 (3). In their paper, they reported that the diagnosis of CNPA can be confirmed with pathological evidence of tissue invasion by the fungus or a response to antifungal treatment and that CNPA is distinct from semi-invasive pulmonary aspergillosis because true fungal invasion is not demonstrated microscopically in semiinvasive pulmonary aspergillosis despite the presence of considerable lung destruction (2, 3) . However, the most recent official ATS statement (5) and the most recent review article published on aspergillosis (6) categorized CNPA and semi-invasive aspergillosis as the same disease entity. In 2003, Denning and coworkers proposed the entities of CCPA and CFPA (4). In 2005, Hope, Walsh and Denning stated that some CNPA patients should be included in the non-angioinvasive invasive pulmonary aspergillosis classification, while others should be included in the category of chronic forms of pulmonary aspergillosis (18) . In 2011, Smith and Denning categorized pulmonary aspergillosis as the following disease entities: simple aspergilloma, CCPA, CFPA, CNPA or subacute invasive aspergillosis and acute invasive aspergillosis (19) . They combined simple aspergilloma, CCPA and CFPA as CPA and restricted CNPA to subacute invasive aspergillosis. We used the classification provided in the 2011 official ATS statement in the present study (5) . Therefore, our classification of CNPA would also include CCPA, CFPA and the CNPA of the Smith and Denning classification (19) .
In the present study, the diagnosis of CNPA was based on a combination of compatible symptoms, compatible radiological findings (20, 21) , positive isolation of Aspergillus species from respiratory specimens and/or positive serum antibodies to Aspergillus. Several Aspergillus antibody detection assays exist (22) . Many patients with CNPA have positive serum IgG precipitating antibodies to Aspergillus (6) . To detect serum Aspergillus antibodies in the present study, we used complement fixation tests, which proved to be both sensitive and specific for detecting antibodies to A. Fumigatus (23) .
Itraconazole, voriconazole, micafungin, amphotericin B and liposomal amphotericin B have all been used to treat the various types of CPA, including CNPA (3-5, 7, 9-13, 16, 24-29) . A multicenter trial in Japan proved that micafungin is as effective as voriconazole (24) . In the present study, the first-line treatments included no treatment in 33.5% of the HR: hazard ratio, CI: confidence interval, Pre-Tb: previous pulmonary tuberculosis, coexistence of old inflammatory change and history of pulmonary tuberculosis, ILD: interstitial lung disease, includes cases of idiopathic pulmonary fibrosis (n=23), collagen vascular disease/usual interstitial pneumonia (n=6), chronic hypersensitivity pneumonitis (n=2), and desquamative interstitial pneumonia (n=1), NTM: nontuberculous mycobacteriosis, BMI: body mass index, Hb: hemoglobin, CRP: C-reactive protein, ITCZ: itraconazole, MCFG: micafungin, VRCZ: voriconazole *Others includes prior lung operation (n=10), active pulmonary tuberculosis (n=5), bulla (n=4), pneumothorax (n=4), and other (n=9) cases. patients, itraconazole in 28.9% of the patients, micafungin in 23.7% of the patients, voriconazole in 11.3% of the patients and amphotericin B (including liposomal amphotericin B) in 2.6% of the patients. Throughout the observational period, 41.8%, 24.7% and 12.4% patients received one, two and three or more antifungal agents, respectively. The median age was highest in the no treatment only patients (73.0 years), while that of the patients receiving three or more antifungal agents was lowest (63.3 years). In the present study, younger patients tended to be more aggressively treated with second-or third-line treatments. The reported mortality rates of CNPA vary (6, 7). Only a Korean report (patient median age: 60 years; median followup: 15 months) described a median survival time, 62 months, for CNPA patients (12) , all of whom received either itraconazole (91%) or intravenous amphotericin B (9%). In the present study (patient median age: 68.5 years; median follow-up: 2.6 years), the overall cumulative 5-year mortality rate was 50.2% and the median survival time was 58 months. Denning and coworkers reported that "mild symptoms, thin-walled quiescent cavities, residual pleural fibrosis and normal inflammatory markers" indicate good long-term medical outcomes of CCPA and CFPA (4); however, no sup-porting data were provided. In the present study, multivariate Cox proportional hazard modeling showed an older age, the presence of systemic comorbidities, baseline corticosteroid use, a BMI of <18.5 kg/m 2 and a CRP level of ! 5.0 mg/ dL to be negative prognostic factors. Denning stated that corticosteroid therapy is an underlying condition in CNPA and that corticosteroid use tends to result in a severe and rapid course (30) . Ohba and coworkers reported BMI to be an independent predictor of the prognosis of CPA patients, while antifungal therapy did not significantly affect survival (14) .
Nam and coworkers reported specific causes of death in 22 patients who died from CNPA to be progression of CNPA (81.8%), complications of surgery for CNPA (4.5%) and infective endocarditis (4.5%) (12) . The specific causes of death in 14 patients who died from CNPA were reported by Hagiwara and coworkers to include respiratory failure due to CNPA or underlying respiratory disease (67.3%) and other pulmonary diseases (21.4%) (13) . Ohba and coworkers reported that specific causes of death in 21 patients dying from CPA included CPA-related (85.7%) and lung cancerrelated causes (14.3%) (14) . The causes of death in the 88 patients who died in the present study were pneumonia (27.3%), CNPA progression (26.1%), ILD (11.4%), lung cancer (3.4%), NTM (3.4%), other pulmonary diseases (8.0%), non-pulmonary diseases (6.8%) and unknown causes (13.6%). The results from these four studies suggest that >80% of CNPA and CPA patients die from respiratory disease. With the exception of one patient, the causes of death in our 41 patients who received no treatment were not related to CNPA itself. If the locus is underlying lung disease, observation without treatment may be one reasonable course of action.
One limitation of this study is its retrospective nature. In addition, clinical and laboratory findings were not available for all patients. Patients who were suspected of having CNPA but did not meet the diagnostic criteria were followed every one to three months. However, BMI and/or blood samples were not always measured every one to three months; thus, when the diagnosis was clearly established, these data were not always available. Second, we classified CPA into two types: aspergilloma and CNPA. Our CNPA definition included not only CNPA, but also CCPA and CFPA. Finally, because the choice of antifungal agent was based on the decision of the attending physician, the duration of treatment varied widely, and because the choice of the second-and third-line treatments was also decided by the attending physician, it was thus impossible to come to a significant conclusion relative to the treatment of CNPA in this retrospective study.
In spite of these limitations, the following points were clarified. An older age, the presence of systemic comorbidities, baseline corticosteroid use, a BMI of <18.5 kg/m 2 and a CRP level of ! 5.0 mg/dL were found to be negative prognostic factors for all-cause CNPA mortality. First-line treatment was not associated with all-cause mortality. In conclusion, when clinical trials are designed and implemented to test the effectiveness of drug therapies in patients with CNPA, the trial patients should be stratified according to these prognostic factors prior to randomization.
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